Read More 1 minute read Analyst Ratings News Price Target Reiteration Cantor Fitzgerald Reiterates Overweight on Marinus Pharma, Maintains $28 Price Target By Benzinga Newsdesk March 8, 8:56 AM Cantor Fitzgerald analyst Charles Duncan reiterates Marinus Pharma (NASDAQ:MRNS) with a Overweight and maintains $28 price target. MRNS
Read More 1 minute read Analyst Ratings News Price Target Reiteration JMP Securities Reiterates Market Outperform on Neuronetics, Maintains $12 Price Target By Benzinga Newsdesk March 8, 8:26 AM JMP Securities analyst David Turkaly reiterates Neuronetics (NASDAQ:STIM) with a Market Outperform and maintains $12 price target. STIM
Read More 1 minute read Analyst Ratings News Price Target Reiteration RBC Capital Reiterates Sector Perform on B2Gold, Maintains $4.25 Price Target By Benzinga Newsdesk March 8, 8:15 AM RBC Capital analyst Josh Wolfson reiterates B2Gold (AMEX:BTG) with a Sector Perform and maintains $4.25 price target. BTG
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on JFrog, Maintains $28 Price Target By Benzinga Newsdesk March 8, 7:36 AM Needham analyst Mike Cikos reiterates JFrog (NASDAQ:FROG) with a Buy and maintains $28 price target. FROG
Read More 1 minute read Analyst Ratings News Price Target Reiteration Needham Reiterates Buy on Pros Holdings, Maintains $35 Price Target By Benzinga Newsdesk March 8, 7:35 AM Needham analyst Scott Berg reiterates Pros Holdings (NYSE:PRO) with a Buy and maintains $35 price target. PRO
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Immunocore Hldgs, Maintains $90 Price Target By Benzinga Newsdesk March 8, 7:23 AM HC Wainwright & Co. analyst Patrick Trucchio reiterates Immunocore Hldgs (NASDAQ:IMCR) with a Buy and maintains $90 price target. IMCR
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Neutral on Eliem Therapeutics, Maintains $6 Price Target By Benzinga Newsdesk March 8, 7:21 AM HC Wainwright & Co. analyst Douglas Tsao reiterates Eliem Therapeutics (NASDAQ:ELYM) with a Neutral and maintains $6 price target. ELYM
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Corbus Pharmaceuticals, Maintains $3 Price Target By Benzinga Newsdesk March 8, 7:12 AM HC Wainwright & Co. analyst Andrew Fein reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $3 price target. CRBP
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on ProPhase Labs, Maintains $15 Price Target By Benzinga Newsdesk March 8, 7:11 AM HC Wainwright & Co. analyst Yi Chen reiterates ProPhase Labs (NASDAQ:PRPH) with a Buy and maintains $15 price target. PRPH
Read More 1 minute read Analyst Ratings News Price Target Reiteration HC Wainwright & Co. Reiterates Buy on Scholar Rock Holding, Maintains $30 Price Target By Benzinga Newsdesk March 8, 7:07 AM HC Wainwright & Co. analyst Andres Maldonado reiterates Scholar Rock Holding (NASDAQ:SRRK) with a Buy and maintains $30 price target. SRRK